Rochester Medical Corporation

Rochester Medical — Jefferies 2010 Global Life Sciences Conference

39 slides from Rochester Medical's conference presentation, Jun 10, 2010

  1. Slide 1: Rochester Medical Corporation Jefferies 2010 Global Life Sciences Conference

    Rochester Medical Corporation Jefferies 2010 Global Life Sciences Conference The Grand Hyatt, New York June 10, 2010

  2. Slide 2: Outline

    Outline Corporate Overview Revenue Growth Products Opportunities

  3. Slide 3: Company Facts

    Company Facts Develop, Manufacture and Sell Disposable Incontinence and Bladder Drainage Devices Four Major Product Categories Rochester Medical Brand Sold in Over 75 Countries Focus on North America and Europe Private Label Sales to Major Medical Device Companies 33 Acres in Stewartville, Minnesota

  4. Slide 4: Sales - Brand Focused Growth, Private Label Stability

    Sales -Brand Focused Growth Private Label "Stability" F04 F05 F06 F07 F08 F09 F09* RM Branded 6551000 7351000 10797000 19226000 23848000 23265095 26331495 Private Label 2427665 8591000 10834000 13437000 11344000 11543445 11543445 *F09 if £ to $ exchange rates had not fallen (1.966 - 1.558)

  5. Slide 5: Q2 2010 Sales

    Q2 2010 Sales Q2-09 Q2-10 RM Branded 5508491 7216026 Private Label 2936538 2580504 19% Overall Sales Growth 29% U.S./U.K. Branded Growth 71% US Foley Sales Growth 37% US Intermittent Growth Year to Date

  6. Slide 6: Market Opportunity

    Market Opportunity Products/Markets U.S. U.K. Rest of Europe Total Male External Catheter $50 $18 $60 $128 Intermittent $400 $100 $300 $800 FemSoft Foley Catheter TBD $400 TBD $50 TBD $70 TBD $520 TOTALS $850 $168 $430 1,448 ($ in millions) At Home Care At Home Care AcuteCare At Home Care

  7. Slide 7: Marketing Overview: Acute Care, Homecare

    Marketing Overview Acute Care Homecare

  8. Slide 8: Acute Care Recent Highlights

    Acute Care Recent Highlights: Introduced StrataSI Silicone Foley Catheters with Comfort Layered Technology The most significant advancement in 40 years Introduced StrataNF Anti-infection Foley Catheter The only anti-infection Foley Catheter indicated for reducing CAUTI Numerous hospitals at various

  9. Slide 9: Acute Care Recent Highlights: GPO Contracts

    Acute Care Recent Highlights: Three new/renewed GPO contracts Broadlane Premier (3yr renewal) Novation (3yr renewal) 90% of US Market is Latex We believe Strata Technology obsoletes the need for Latex Strata Technology gives hospitals all the benefits of silicone without sacrificing comfort More adv

  10. Slide 10: Acute Care Communications Campaign: Direct Mail

    Acute Care Communications Campaign Direct Mail

  11. Slide 11: Acute Care Communications Campaign: Trade Shows

    Acute Care Communications Campaign Aggressive trade show promotion SHEA/ IDSA/ APIC Decennial AUA APIC

  12. Slide 12: Go ahead, touch it.

    Go ahead, touch it. — ~ The ula so, ule smoot, rade, -sleone Foley.

  13. Slide 13: Foley realized.

    Foley realized.

  14. Slide 14: Homecare Highlights: Emphasis on Magic3 Intermittent Catheters

    Homecare Highlights: Emphasis on Magic3 Intermittent Catheters

  15. Slide 15: Homecare Proprietary Technology

    Homecare Proprietary Technology Unique Features and Benefits with: Clinical Appeal Consumer Appeal

  16. Slide 16: Homecare Magic is Best in Class

    Homecare Magic is Best in Class Unique composite Three distinct Layers Easy Handling Gentle on sensitive tissue Proprietary Hydrophilic Surface Proprietary Antibacterial Surface Phthalate-free

  17. Slide 17: Homecare Clinical Selling

    Homecare Clinical Selling Adult and Pediatric Urology Offices Rehab Centers MS Clinics Spina Bifida Clinics Hospitals

  18. Slide 18: Homecare Clinical Sell with Consumer Appeal: Journal Advertising

    Homecare Clinical Sell with Consumer Appeal Targeted Journal Advertising

  19. Slide 19: Homecare Clinical Sell with Consumer Appeal: End User Events

    Homecare Clinical Sell with Consumer Appeal End User Events

  20. Slide 20: Homecare Clinical Sell with Consumer Appeal: Direct Mail

    Homecare Clinical Sell with Consumer Appeal Direct Mail

  21. Slide 21: Homecare Communications Campaign: Micro-site

    Homecare Communications Campaign: Micro-site

  22. Slide 22: Homecare Communications Campaign: Product Brochure

    Homecare Communications Campaign: Product Brochure

  23. Slide 23: Homecare Magic Technology in the UK

    Homecare Magic technology in the UK Branded as Hydrosil Aggressive Clinical Campaign Great acceptance Direct to Patient supply Full reimbursement Sterile Hydrophilic Market

  24. Slide 24: Homecare Magic Technology Europe and Rest of the World

    Homecare Magic technology Europe and Rest of the World Sold thru Independent Distribution Partners With Field Sales Country Specific Territories

  25. Slide 25: FemSoft Highlights

    FemSoft Highlights: Completed CMS application for reimbursement Granted unique HCPCS code Medicare coverage initiated Jan.1, 2010 Approved for reimbursement in the UK UK coverage initiated Jan. 1, 2010

  26. Slide 26: FemSoft 2010 Pilot Market Introductions

    FemSoft 2010 Pilot Market Introductions: Charlotte, NC Clinic and consumer focus Southern Florida Direct to consumer distributor focus United Kingdom Clinical - (Continence Care Specialists)

  27. Slide 27: FemSoft Communications Campaign: Clinical Sell

    FemSoft Communications Campaign: Clinical Sell Print Advertising Out-of-Home Advertising Television Ad Lead/Referral/Follow-up Process

  28. Slide 28: FemSoft: Live with confidence...

    FemSoft Live with confidence...

  29. Slide 29: FemSoft Communications Campaign: DTC micro-site

    FemSoft Communications Campaign: DTC - micro-site:

  30. Slide 30: FemSoft Commercial

    4 FemSoft Commercial a

  31. Slide 31: FemSoft Results so Far

    FemSoft Results so Far Very Positive Clinical Response Urology Ob-Gyn High Consumer Interest Modest Number of Prescriptions

  32. Slide 32: Recent Customer Feedback

    Recent Customer Feedback "FemSoft saved my life! (Before FemSoft) I had to quit working. When I found out about them, it really improved my life." "I can ride bike without worry. It takes little practice but worth while." "I have been able to go walk and shop without fear of getting wet."

  33. Slide 33: Recent Customer Feedback

    Recent Customer Feedback "Start using them as soon as possible - they will give you your freedom back." "FemSoft is easy, comfortable and reliable! Don't be miserable, be safe with FemSoft! Would not be able to play tennis without FemSoft." "It is easy to use, comfortable to the point that I forget

  34. Slide 34: Only device of its kind

    Only device of its kind Advanced, proprietary, patented Elegant solution for female incontinence Unique to Rochester Medical

  35. Slide 35: U.S. and UK FemSoft Potential

    U.S. and UK FemSoft Potential Over 14 million Clinically Incontinent Females 5% Penetration Assuming 2 devices per day is over a $1 Billion dollar market

  36. Slide 36: FemSoft Market Acceptance Difficult to Predict

    FemSoft Market Acceptance Difficult to Predict Stress Incontinence is a very significant problem Current Users satisfied with FemSoft solution Most women's first reaction to concept of urethral insertion is hesitancy, caution, uncertainty. Consumer and clinical education needed to instill confidence

  37. Slide 37: Summary

    Summary Excellent Opportunities Rochester Medical in strong position to achieve success Superior, advanced products and technology New market dynamics (reimbursement policies) New focus on infection control Magic Intermittents off to a great start! StrataSI and StrataNF off to a great start! Potenti

  38. Slide 38: Market Opportunity

    Market Opportunity Products/Markets U.S. U.K. Rest of Europe Total Male External Catheter $50 $18 $60 $128 Intermittent $400 $100 $300 $800 FemSoft Foley Catheter TBD $400 TBD $50 TBD $70 TBD $520 TOTALS $850 $168 $430 1,448 ($ in millions) At Home Care At Home Care AcuteCare At Home Care

  39. Slide 39: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties, including the uncertainty of estimated revenues and profits, as well as the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic r

Rochester Medical — Jefferies 2010 Global Life Sciences Conference on 6ix